title: Stability-Indicating HPLC Method for the Determination of Cefcapene Pivoxil.
abstract: The stability-indicating LC assay method was developed and validated for quantitative determination of cefcapene pivoxil in the presence of degradation products formed during forced degradation studies. An isocratic RP-HPLC method was developed with a Lichrospher RP-18 (250 mm × 4.6 mm, 5 μm) column and the mobile phase composed of 45 volumes of acetonitrile and 55 volumes of mixture composed of citric acid 10 mmol L-1and potassium chloride 18 mmol L-1. The flow rate of the mobile phase was 1 mL min-1. Detection wavelength was 270 nm and temperature was 30 °C. Cefcapene pivoxil, similar to other cephalosporins, was subjected to stress conditions of degradation in aqueous solutions including hydrolysis, oxidation, and thermal degradation. The method was validated with regard to linearity, accuracy, precision, selectivity, and robustness. The method was applied successfully for the determination of cefcapene pivoxil during kinetic studies in aqueous solutions (pH and thermal degradation) and in solid state (oxidative, thermal, and radiolytic degradation).
authors.affiliation: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland.
authors.forename: Przemysław
authors.initials: P
authors.lastname: Zalewski
authors.forename: Judyta
authors.initials: J
authors.lastname: Cielecka-Piontek
authors.forename: Piotr
authors.initials: P
authors.lastname: Garbacki
authors.forename: Anna
authors.initials: A
authors.lastname: Jelińska
authors.forename: Marta
authors.initials: M
authors.lastname: Karaźniewicz-Łada
keywords: Cefcapene pivoxil; Column liquid chromatography; Stability-indicating method
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2604-9
references.pmid: 15215116
references.citation: Acta Pol Pharm. 2005 Mar-Apr;62(2):89-94
references.pmid: 16161347
references.citation: Int J Antimicrob Agents. 2001 Nov;18(5):489-94
references.pmid: 11711266
references.citation: Acta Pol Pharm. 2009 Sep-Oct;66(5):563-9
references.pmid: 19894653
references.citation: Acta Pol Pharm. 2008 Mar-Apr;65(2):261-5
references.pmid: 18666435
references.citation: Chem Pharm Bull (Tokyo). 1990 Jul;38(7):1998-2002
references.pmid: 2268903
references.citation: Acta Pol Pharm. 2005 May-Jun;62(3):183-7
references.pmid: 16193810
references.citation: J Pharm Biomed Anal. 2003 Aug 21;32(6):1181-7
references.pmid: 12907262
references.citation: J Pharm Biomed Anal. 2004 Sep 3;35(5):1273-7
references.pmid: 15336372
references.citation: Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1406-11
references.pmid: 18827379
references.citation: J Infect Chemother. 2011 Aug;17(4):499-503
references.pmid: 21249415